NeoGenomics, Inc. Restructuring and Related Cost, Incurred Cost
NeoGenomics, Inc. (NEO) reported Restructuring and Related Cost, Incurred Cost of $1.90 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2023-11-06
- NeoGenomics, Inc. restructuring and related cost, incurred cost for the quarter ending 2023-09-30 was $1.90M.
- NeoGenomics, Inc. restructuring and related cost, incurred cost for the quarter ending 2023-06-30 was $2.75M.
- NeoGenomics, Inc. restructuring and related cost, incurred cost for the quarter ending 2023-03-31 was $4.12M.
- NeoGenomics, Inc. restructuring and related cost, incurred cost for fiscal 2022 was $3.80M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.90M 10-Q · filed 2023-11-06 | $4.64M derived: sum of 2 quarters · filed 2023-11-06 | $8.77M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2023-06-30 | $2.75M 10-Q · filed 2023-11-06 | $6.87M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2023-03-31 | $4.12M 10-Q · filed 2023-11-06 | |||
| 2022-12-31 | $3.80M 10-K · filed 2023-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |